Novel Method for Selecting Immunosuppressive Histone Deacetylase (HDAC) Inhibitors with Minimal Thrombocytopenia(Molecular and Cell Biology)
スポンサーリンク
概要
- 論文の詳細を見る
Histone deacetylase (HDAC) inhibitors repress interleukin-2 (IL-2) gene expression in T cells and possess immunosuppressive activity in vivo. In addition to its immunosuppressive activity, HDAC inhibitors block GATA binding protein-1 (GATA-1) gene expression in megakaryocytes and elicit thrombocytopenia. In this report we state that for a given immunosuppressive dose of HDAC inhibitor, the ratio of GATA-1 reporter gene activity relative to IL-2 reporter gene assay (G/I ratio of measured IC_<50>) can be predictive of a HDAC inhibitor's thrombocytopenic effect. This study utilized nine HDAC inhibitors at a minimal effective dose in a rat heterotopic cardiac transplantation model and the resultant G/I ratios and platelet depletion rates were highly correlated (r=0.933). These results indicate that calculation of G/I ratio can be a novel method for selecting immunosuppressive HDAC inhibitor having minimal thrombocytopenic effect which will benefit the search for new immunosuppressants of greater safety and efficacy.
- 社団法人日本薬学会の論文
- 2008-02-01
著者
-
Yanagihara Takehiko
Pharmacology Research Laboratories Astellas Pharma Inc.:astellas Research Institute Of America Llc.
-
MATSUOKA Hideaki
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
FUJIMURA Takao
Molecular Medicine Research Laboratories, Astellas Pharma Inc.
-
UNAMI Akira
Drug Safety Research Laboratories, Astellas Pharma Inc.
-
YAMADA Toshiko
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
NOTO Takahisa
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
TAKATA Yoko
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
YOSHIZAWA Katsuhiko
Drug Safety Research Laboratories, Astellas Pharma Inc.
-
MORI Hiroaki
Fermentation Research Laboratories, Astellas Pharma Inc.
-
ARAMORI Ichiro
Molecular Medicine Research Laboratories, Astellas Pharma Inc.
-
MUTOH Seitaro
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
Takata Yoko
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Noto Takahisa
Department Of Applied Pharmacology 1 Pharmacology Research Labs Astellas Pharma Inc.
-
Noto Takahisa
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Mutoh Seitaro
Pharmacology Res. Labs Astellas Pharma Inc. Jpn
-
Yamada Toshiko
Astellas Research Institute Of America Llc.
-
Aramori Ichiro
Molecular Medicine Research Laboratories Astellas Pharma Inc.
-
Yoshizawa Katsuhiko
Drug Safety Research Laboratories Astellas Pharma Inc.
-
Mori Hiroaki
Fermentation Research Laboratories Astellas Pharma Inc.
-
Fujimura Takao
Molecular Medicine Research Laboratories Astellas Pharma Inc.
-
Matsuoka Hideaki
Pharmacology Research Laboratories Astellas Pharma Inc.:astellas Research Institute Of America Llc.
-
Unami Akira
Drug Safety Research Laboratories Astellas Pharma Inc.
-
Yamada Toshiko
Pharmacology Research Laboratories Astellas Pharma Inc.
関連論文
- Novel Method for Selecting Immunosuppressive Histone Deacetylase (HDAC) Inhibitors with Minimal Thrombocytopenia(Molecular and Cell Biology)
- Tacrolimus (FK506) Limits Accumulation of Granulocytes and Platelets and Protects against Brain Damage after Transient Focal Cerebral Ischemia in Rat(Pharmacology)
- Unique Properties of Coactivator Recruitment Caused by Differential Binding of FK614, an Anti-diabetic Agent, to Peroxisome Proliferator-Activated Receptor γ(Molecular and Cell Biology)
- FK614, a Novel Peroxisome Proliferator-Activated Receptor γ Modulator, Induces Differential Transactivation Through a Unique Ligand-Specific Interaction With Transcriptional Coactivators
- Efficacy of Oral Treatment With Tacrolimus in the Renal Transplant Model in Cynomolgus Monkeys
- Effect of a New Immunosuppressant Histon Deacetylase (HDAC) Inhibitor FR276457 in a Rat Cardiac Transplant Model(Pharmacology)
- Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations
- Determination of Antifungal Activities in Serum Samples from Mice Treated with Different Antifungal Drugs Allows Detection of an Active Metabolite of Itraconazole
- Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds
- AS1387392, a novel immunosuppressive cyclic tetrapeptide compound with inhibitory activity against mammalian histone deacetylase
- Bioconversion of AS1387392 : bioconversion studies involving Amycolatopsis azurea JCM 3275